Fennec Pharmaceuticals Inc. revenue
Fennec Pharmaceuticals Inc.'s revenue was $44.6m in fiscal 2025, down 6.1% on the year before. Since fiscal 2020 ($200,000) it has grown at a compound 286.5% a year. Over the last twelve months it was $59.2m.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 21 | 48 | 45 | 59 |
| Growth on the year before | — | — | — | — | — | — | — | — | — | — | +667.5% | +>999% | +123.7% | −6.1% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | 1 | 20 | — | — | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. | $59.2m | 77.8% | 566.5% |
| Intellia Therapeutics, Inc. | $59.5m | 12.6% | 3.9% |
| Invivyd, Inc. | $58.4m | 26.3% | — |
| Nektar Therapeutics | $54.6m | -27.2% | -14.6% |
| Clinuvel Pharmaceuticals Ltd | $64.3m | 5.2% | — |
| Tango Therapeutics, Inc. | $53.8m | 121.5% | 16.9% |
Compare with peers
- Intellia Therapeutics, Inc. revenue
- Invivyd, Inc. revenue
- Nektar Therapeutics revenue
- Clinuvel Pharmaceuticals Ltd revenue
- Tango Therapeutics, Inc. revenue
Head to head: FENC vs NTLAFENC vs IVVDFENC vs NKTR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies